{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:31Z","timestamp":1790983111283,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,17]]},"DOI":"10.7759\/cureus.112861","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:21:48Z","timestamp":1784301708000},"source":"Crossref","is-referenced-by-count":1,"title":["Semaglutide for Refractory Reactive Hypoglycaemia: A Case Report"],"prefix":"10.7759","author":[{"given":"Harshni","family":"Kalimuthu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathma","family":"Seekkuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sona","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Postprandial (reactive) hypoglycemia","volume":"28","author":"Service FJ","year":"1999","unstructured":"Service FJ. Postprandial (reactive) hypoglycemia. Endocrinol Metab Clin North Am. 1999, 28:603-18.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1410","article-title":"Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline","volume":"94","author":"Cryer PE","year":"2009","unstructured":"Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, Service FJ. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009, 94:709-28. 10.1210\/jc.2008-1410","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1332702","article-title":"Proposed treatment strategy for reactive hypoglycaemia","volume":"15","author":"Younes YR","year":"2024","unstructured":"Younes YR, Cron N, Field BC, et al.. Proposed treatment strategy for reactive hypoglycaemia. Front Endocrinol (Lausanne). 2024, 15:1332702. 10.3389\/fendo.2024.1332702","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst JJ","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007, 87:1409-39. 10.1152\/physrev.00034.2006","journal-title":"Physiol Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker DJ","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018, 27:740-56. 10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20 Suppl 1","author":"Nauck MA","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018, 20 Suppl 1:5-21. 10.1111\/dom.13129","journal-title":"Diabetes Obes Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck MA","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021, 46:101102. 10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23600","article-title":"The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review","volume":"31","author":"Llewellyn DC","year":"2023","unstructured":"Llewellyn DC, Logan Ellis H, Aylwin SJ, et al.. The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review. Obesity (Silver Spring). 2023, 31:20-30. 10.1002\/oby.23600","journal-title":"Obesity (Silver Spring)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0504","article-title":"GLP1 analogs as treatment of postprandial hypoglycemia following gastric bypass surgery: a potential new indication?","volume":"169","author":"Abrahamsson N","year":"2013","unstructured":"Abrahamsson N, Engstr\u00f6m BE, Sundbom M, Karlsson FA. GLP1 analogs as treatment of postprandial hypoglycemia following gastric bypass surgery: a potential new indication?. Eur J Endocrinol. 2013, 169:885-9. 10.1530\/EJE-13-0504","journal-title":"Eur J Endocrinol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2174\/0118715303318399240715065513","article-title":"Efficacy of semaglutide in reactive hypoglycemia related to dumping syndrome after bariatric surgery","volume":"24","author":"Fiore A","year":"2024","unstructured":"Fiore A, Gaetano S, Ausilia L, Federica S, Giulia S, Damiano G. Efficacy of semaglutide in reactive hypoglycemia related to dumping syndrome after bariatric surgery. Endocr Metab Immune Disord Drug Targets. 2024, 24:5. 10.2174\/0118715303318399240715065513","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1600","article-title":"International consensus on use of continuous glucose monitoring","volume":"40","author":"Danne T","year":"2017","unstructured":"Danne T, Nimri R, Battelino T, et al.. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017, 40:1631-40. 10.2337\/dc17-1600","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range","volume":"42","author":"Battelino T","year":"2019","unstructured":"Battelino T, Danne T, Bergenstal RM, et al.. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care. 2019, 42:1593-603. 10.2337\/dci19-0028","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00319-9","article-title":"Continuous glucose monitoring and metrics for clinical trials: an international consensus statement","volume":"11","author":"Battelino T","year":"2023","unstructured":"Battelino T, Alexander CM, Amiel SA, Arreaza-Rubin G, Beck RW, Bergenstal RM. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol. 2023, 11:42-57. 10.1016\/S2213-8587(22)00319-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-3815","article-title":"Analysis of the polarization states of the alveolar macrophages in chronic obstructive pulmonary disease samples based on miRNA-mRNA network signatures","volume":"9","author":"Shen W","year":"2021","unstructured":"Shen W, Wang S, Wang R, Zhang Y, Tian H, Yang X, Wei W. Analysis of the polarization states of the alveolar macrophages in chronic obstructive pulmonary disease samples based on miRNA-mRNA network signatures. Ann Transl Med. 2021, 9:1333. 10.21037\/atm-21-3815","journal-title":"Ann Transl Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley RE","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, et al.. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018, 6:275-86. 10.1016\/S2213-8587(18)30024-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau J","year":"2015","unstructured":"Lau J, Bloch P, Sch\u00e4ffer L, et al.. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015, 58:7370-80. 10.1021\/acs.jmedchem.5b00726","journal-title":"J Med Chem"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/511778-semaglutide-for-refractory-reactive-hypoglycaemia-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:21:49Z","timestamp":1784301709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/511778-semaglutide-for-refractory-reactive-hypoglycaemia-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.112861","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}